Login to Your Account



MGI’s Irofulven Phase III Pancreatic Trial Stopped; Stock Tumbles

By Karen Young


Thursday, April 18, 2002
MGI Pharma Inc. said it stopped a Phase III trial of irofulven for gemcitabine-refractory pancreatic cancer, thus ending development of the product in that indication, but also said that pivotal Phase III trials of palonosetron achieved the primary endpoint. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription